EGFR and lung carcinoma: Colorectal, biliary tract, pancreatic, and lung carcinomas are similar with respect to their levels of EGFR expression and EGFR signaling; however, a combined inhibition of EGFR and BRAF is accepted mainly for colorectal malignancies, while the remaining cancer types are treated by BRAF and MEK antagonists.